Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-37822681 in Schizophrenia
NCT00728195Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of JNJ-37822681 in schizophrenia, sponsored by Johnson & Johnson. Started Nov 2008; status: completed.
02
Drugs
JNJ-37822681
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00728195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00728195.